Immunotherapy in the treatment of stage III NSCLC:
Towards a new standard of care
To view the complete article click
here (pdf format)
Approximately one-third of patients with non-small cell lung cancer (NSCLC) are diagnosed with stage III disease, where cancer is locally advanced and not amenable to curative surgical treatment. The current
standard of care involves combining radiation therapy (RT) with chemotherapy. Despite a great number of trials with new agents, doses and combinations, this standard of care has not changed in decades and the 5-year survival remains low. The PACIFIC trial results have shown improved survival with the addition of immunotherapy to the standard of care. In this article, we will look at this development in context.